The Impact of Timing of Stent Removal on the Incidence of UTI, Recurrence, Symptomatology, Resistance, and Hospitalization in Renal Transplant Recipients

Table 1

Renal transplant recipients’ characteristics.

	Total 279	Early 114	Late 165
Stent removal time (mean ± SD)	35.3 ± 28.0	14.1 ± 4.6	49.9 ± 28.1	<0.001
Age (mean ± SD)	43.4 ± 15.8	44.1 ± 16.2	42.9 ± 15.5	0.544
Gender
Male	165	68	97	0.902
	59.10%	59.60%	58.80%
Female	114	46	68
	40.90%	40.40%	41.20%
Donor type				0.031
Deceased	55	15	40
	19.70%	13.20%	24.20%
Living	224	99	125
	80.30%	86.80%	75.80%
Transplant abroad	21	11	10	0.356
	7.50%	9.60%	6.10%
Preemptive transplant	21	9	12	1
	7.6%	8.00%	7.30%
Diabetes mellitus
Type I	25	8	17	1
	26.60%	25.80%	27.00%
Type II	69	23	46
	73.40%	74.20%	73.00%
Induction therapy
Basiliximab	107	68	104	0.617
	38.40%	60.20%	63.00%
ATG	172	46	61
	61.60%	40.40%	37.00%
Serum creatinine in mmol/L (mean ± SD)
At 1 month	103.7 ± 47.2	99.7 ± 34.5	106.4 ± 54.2	0.244
At 6 months	99.0 ± 34.0	93.5 ± 21.1	102.7 ± 40.2	0.014
Rejection within 6 months	22	6	16
	7.90%	5.30%	9.70%	0.416
BK	19	9	10	0.632
	6.80%	7.90%	6.10%
UTI antibiotic prophylaxis
TMP/SMX double strength + norfloxacin	70	13	57	<0.001
	25.10%	11.40%	34.50%
TMP/SMX single strength	209	101	108
	74.90%	88.60%	65.50%
Pretransplant urological abnormalities
Urethral stricture	11	5	6	0.763
	3.90%	4.40%	3.60%
Neurogenic bladder	10	3	7	0.535
	3.60%	2.60%	4.20%
Vesicoureteral reflux (VUR)	7	1	6	0.246
	2.50%	0.90%	3.60%
Emergent stent removal due to stent migration	6	5	1	0.048
	2.1%	1.7%	0.04%